
Commentary|Videos|December 9, 2025
Decoding Developments in GVHD Management With Drs Salhotra and Negrin
Amandeep Salhotra, MD, and Robert Negrin, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in graft-vs-host disease presented during the 2025 ASH Annual Meeting & Exposition.
Advertisement
Amandeep Salhotra, MD, of City of Hope, and Robert Negrin, MD, of Stanford Medicine, sit down with Chandler Park, MD, FACP, of Norton Cancer Institute, to discuss the latest abstracts in graft-vs-host disease presented during the 2025 ASH Annual Meeting & Exposition.
Advertisement
Related to this article

Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.

Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

An interim phase 1/2 trial update found that DB107-RRV plus DB107-FC could be given in combination with radiation in newly diagnosed high-grade glioma.

Many patients with IDH-mutant glioma continued to receive vorasidenib as directed in the real-world GLIO-ADHERE claims analysis.

Mirdametinib produced stable disease or partial responses in adults and children with plexiform neurofibromas who had received another MEK inhibitor.

Longer follow-up of the phase 3 INDIGO trial showed that vorasidenib lowered seizure rates in IDH-mutant glioma, an effect driven by oligodendroglioma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
3
ESMO 2026 Data Highlight ADC Activity in Brain Metastases and TNBC
4
Galinpepimut-S Improves OS in AML in Second or Later Remission
5



